Efalizumab-induced lupus-like syndrome.
Durox
Hélene
H
Sparsa
Agnès
A
Loustaud-Ratti
Véronique
V
Prey
Sorilla
S
Gondran
Guillaume
G
Manea
Petrus
P
Vidal
Elisabeth
E
Bedane
Christophe
C
D000410:Alanine Transaminase / Q000097:blood; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001219:Aspartate Aminotransferases / Q000097:blood; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced*; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D013577:Syndrome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; C472181:efalizumab